Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

Int J Neuropsychopharmacol. 2004 Dec;7(4):489-93. doi: 10.1017/S1461145704004614. Epub 2004 Sep 22.

Abstract

We performed an association study between four candidate genes, DRD2, DRD3, DRD4 and 5-HT2A for the presence of tardive dyskinesia (TD) on 84 patients with residual schizophrenia. The sample was evaluated again for the presence of TD after an interval of 3 years. The first group did not exhibit TD in either observation (n=34) while in the second group of patients exhibited TD in at least one of the observations (n=20+18). The clinical and socio-demographic characteristics were not significantly different between the two groups; the genetic analysis revealed a significant correlation between the C/C genotype of 5-HT2A and TD (p=0.017). An association trend was observed between the 'short' variant of DRD4 and TD (p=0.022). We did not observe any significant association for the DRD2 and DRD3 polymorphisms.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects*
  • DNA / genetics
  • Dyskinesia, Drug-Induced / epidemiology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Receptor, Serotonin, 5-HT2A / genetics*
  • Receptors, Dopamine D2 / genetics*
  • Receptors, Dopamine D3
  • Receptors, Dopamine D4
  • Reverse Transcriptase Polymerase Chain Reaction
  • Schizophrenia / complications*
  • Schizophrenia / genetics*
  • Schizophrenic Psychology

Substances

  • Antipsychotic Agents
  • DRD3 protein, human
  • DRD4 protein, human
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • Receptors, Dopamine D4
  • DNA